Dalton Pharma Services Announces Development & Manufacturing Agreement
Dalton Pharma Services recently announced the signing of a drug development and manufacturing services agreement with Cerium Pharmaceuticals, Inc., an emerging biopharmaceutical company based in Gaithersburg, MD. Cerium is dedicated to the development and commercialization of medicines for patients with rare (orphan) diseases.
In support of Cerium’s drug development program, Dalton Pharma Services will provide formulation development, cGMP liquid filling, analytical method validation, quality control release testing, and ICH stability services.
“Our expert capabilities in formulation development and sterile fill/finish of APIs combined with our strength in cGMP API manufacturing has led to the signing of this important drug development and manufacturing agreement,” said Peter Pekos, President and CEO. “We are excited to have this opportunity and look forward to participating in Cerium’s drug development program, which has great promise for providing a therapy for a major unmet medical need.”
Gregg Lapointe, CEO of Cerium, remarked “Dalton is an excellent fit for our needs, and we are delighted to be partnering with a company whose clients focus and commitment to quality match our own. Cerium will benefit greatly from having Dalton’s facilities, experience, technical expertise, and array of integrated services to move our drug from R&D to cGMP manufacturing.”
Cerium Pharmaceuticals seeks to develop and commercialize medicines for rare and ultra-rare diseases, no matter how small the patient population. Its goal is to address unmet medical needs by leveraging the basic discovery work performed by others and entering after project feasibility is established. From this point, the company creates collaborative networks tailored to each project, which provide a wide range of support for drug candidates.
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved and FDA registered cGMP contract service provider of integrated chemistry, drug development and manufacturing services to the pharmaceutical and biotechnology industries. The company brings 30 years of experience to its clients’ projects and emphasize quality, speed, and flexibility.
Dalton can accelerate drug development programs by integrating process development, cGMP API manufacturing, and sterile or solid finished dose manufacturing all at a single location. For the full range of in-house services including cGMP sterile fill/finish services, visit www.dalton.com
Total Page Views: 1816
